Kyverna Therapeutics reported one-year data supporting durability for its autoimmune CAR-T candidate miv-cel in stiff person syndrome. The company framed the results as bolstering an FDA submission ahead of regulatory review in a rare autoimmune indication with limited effective options. Kyverna’s update follows intensifying attention in the broader autoimmune CAR-T category, where safety signals at peers have raised scrutiny for risk-benefit and long-term monitoring. For patients, CAR-T in autoimmune disease typically requires careful management of immune effects and sustained follow-up to evaluate both efficacy durability and adverse events. The company’s readout also highlights the field’s ongoing shift toward longer-term datasets in rare disorders, where single-study timelines can be difficult to interpret without multi-year outcomes.